HRS9531 injection Placebo

DRUG5 trials

Sponsors

Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Overweight or ObesityType 2 Diabetes

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

CompletedNCT06762600

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2025-01-16End: 2026-03-12Updated: 2026-04-30

Phase 2

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

CompletedNCT05881837

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2023-06-13End: 2024-10-13Updated: 2025-04-30

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

CompletedNCT05966272

Fujian Shengdi Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2023-08-12End: 2024-09-24Updated: 2025-05-07

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

CompletedNCT06054698

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2023-10-16End: 2024-09-09Updated: 2026-05-22

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

Not yet recruitingNCT07660848

Fujian Shengdi Pharmaceutical Co., Ltd.Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Start: 2026-07-01End: 2028-07-01Target: 160Updated: 2026-06-22